Clinical Trial Update: Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a doxorubicin/cyclophosphamide regimen followed by paclitaxel, trastuzumab, and lapatinib in HER2-positive breast cancer; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Lapatinib (Lapatinib)
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-03-13